Study of How People Make Decisions About Prostate Cancer Risk
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to learn how people with BRCA1/2 mutations respond to genetic risk modifier testing. The researchers will learn more about how people make choices about their health care, including about methods to screen for prostate cancer. Researchers are also doing this study to learn about how the genetic risk modifier test affects people's thoughts and feelings.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek między 45 a 70 lat
- •Urodzony jako mężczyzna
- •Potwierdzona mutacja BRCA1/2 w badaniu genetycznym przeprowadzonym w akredytowanym laboratorium
- •Biegły w języku angielskim
✗ Disqualifies
- •Diagnoza raka prostaty
- •Poważne zaburzenia psychiczne lub problemy z pamięcią, które mogą utrudnić udział w badaniu
- •Bieżące leczenie raka
- •Uczestnictwo w innym badaniu klinicznym dotyczącym ryzyka raka prostaty
Simplified criteria — AI translation
Trial details
- Minimum age
- 45 Years
- Maximum age
- 70 Years
- Last updated (source)
- July 10, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Memorial Sloan Kettering Cancer Center
New York, United States
Trial contact
Jada Hamiliton, PhD, MPH
Kenneth Offit, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.